Alterity Therapeutics Ltd
ASX:ATH

Watchlist Manager
Alterity Therapeutics Ltd Logo
Alterity Therapeutics Ltd
ASX:ATH
Watchlist
Price: 0.008 AUD Market Closed
Market Cap: 87m AUD
Section:
 

Relative Value

ATH doesn't have a meaningful market cap.

The Relative Value of one ATH stock under the Base Case scenario is hidden AUD. Compared to the current market price of 0.008 AUD, Alterity Therapeutics Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ATH Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

194.9
P/S
P/S
Price to Sales
194.9
vs History
88
vs Industry
10
Median 3Y
440.3
Median 5Y
5 305.1
Industry
8
Forward
21.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-7.6
Industry
23.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-8.6
Industry
21.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-8.6
Industry
24.3
More Details
2.1
P/B
P/B
Price to Book Value
2.1
vs History
95
vs Industry
12
Median 3Y
3.2
Median 5Y
3.9
Industry
3.2
More Details
120.8
EV/S
EV/S
Enterprise Value to Sales
120.8
vs History
88
vs Industry
8
Median 3Y
341.2
Median 5Y
4 065.5
Industry
8.1
Forward
13.2
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
30
Median 3Y
-3.9
Median 5Y
-4.9
Industry
5.9
Forward
-2.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
28
Median 3Y
-3.9
Median 5Y
-4.9
Industry
6.2
Forward
-2.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
31
Median 3Y
-4.4
Median 5Y
-6.6
Industry
7.7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
28
Median 3Y
-4.4
Median 5Y
-6.6
Industry
6.3
More Details
5.2
EV/IC
EV/IC
Enterprise Value to IC
5.2
vs History
92
vs Industry
15
Median 3Y
11.6
Median 5Y
20.8
Industry
5.6
More Details

Multiples Across Competitors

ATH Competitors Multiples
Alterity Therapeutics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Alterity Therapeutics Ltd
ASX:ATH
87m AUD 194.9 -7.2 -3.8 -3.8
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 256 368 717.6 -17 605 753.9 -17 276 635.9 -17 238 178.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 103 527.5 -162 089 -196 827.8 -194 581.7
US
Abbvie Inc
NYSE:ABBV
390.6B USD 6.5 166.4 16.2 22.9
US
Amgen Inc
NASDAQ:AMGN
176.9B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
150.3B USD 5.2 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.8B USD 10.2 32.6 24 25
US
Epizyme Inc
F:EPE
94.1B EUR 2 065.7 -527.1 -574 -558.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
84.2B USD 5.9 18.4 17.6 19.9
AU
CSL Ltd
ASX:CSL
84.4B AUD 3.6 18.8 12.7 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.6B USD 16.7 1 229.6 165.8 201.1
P/S Multiple
Revenue Growth P/S to Growth
AU
Alterity Therapeutics Ltd
ASX:ATH
Average P/S: 26 406 778.1
194.9
345%
0.6
IL
C
Can Fite Biopharma Ltd
TASE:CANF
256 368 717.6
140%
1 831 205.1
FR
Pharnext SCA
OTC:PNEXF
34 103 527.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 065.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.9
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.7
46%
0.4
P/E Multiple
Earnings Growth PEG
AU
Alterity Therapeutics Ltd
ASX:ATH
Average P/E: 215.7
Negative Multiple: -7.2 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 605 753.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 089 N/A N/A
US
Abbvie Inc
NYSE:ABBV
166.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.6
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
10%
1.8
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 229.6
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Alterity Therapeutics Ltd
ASX:ATH
Average EV/EBITDA: 38.1
Negative Multiple: -3.8 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 276 635.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 827.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
165.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Alterity Therapeutics Ltd
ASX:ATH
Average EV/EBIT: 45.1
Negative Multiple: -3.8 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 238 178.6 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 581.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
13%
1.5
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
201.1
N/A N/A

See Also

Summary
ATH intrinsic value, competitors valuation, and company profile.
DCF Valuation
ATH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ATH stock valuation using valuation multiples.
Wall Street Estimates
ATH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ATH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.